OakChart

Citius Pharmaceuticals Inc

CTXRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:57 PM ET

0.4806-0.0122 (-2.48%)
2026-11-12 01:53 CET
Market cap
13.53 USD m
Revenue, TTM
7.11 USD m
Net income, TTM
-46.27 USD m
Free cash flow, TTM
-34.87 USD m
EPS diluted, TTM
-2.11
P/E
-
Compare

Price

CTXR against its 20, 50 and 200-day averages
2050200missearnings
0.400.600.801.002.6M5.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CTXRclose 0.4820-day 0.4950-day 0.53200-day 0.640.4852w low

68.8% under the 52-week high of 1.54 on 26 Nov 2025. 52-week low 0.37 on 22 Oct 2026. Last 15 sessions, 75.7% high to low

Volume 0.48× normal · the line is the 50-bar volume average

Profile

CTXR
52-week range, 9% of the way up
0.371.54

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Employees23
IPOOct 02, 2014
Beta1.04
ATR, 14d0.05
Rel volume0.48
Short float21.38%
Insider own1.80%
Inst own5.20%

Snapshot

6 groups

Valuation

Index-
Market Cap13.20M
Enterprise Value12.67M
Income-46.27M
Sales7.11M
Book/sh2.43
Cash/sh0.62
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOOct 02, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S1.86
P/B0.20
P/C0.78
P/FCF-
EV/EBITDA-
EV/Sales1.78
Quick Ratio0.40
Current Ratio0.84
Debt/Eq0.11
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.11
EPS next Y-1.44
EPS next Q-0.41
EPS this Y39.94%
EPS next Y29.06%
EPS next 5Y41.69%
EPS past 3/5Y16.24% 21.29%
Sales past 3/5Y- -
EPS Y/Y TTM57.48%
Sales Y/Y TTM-
EPS Q/Q57.59%
Sales Q/Q-
EarningsAug 14 AMC
EPS/Sales Surpr.5.56% -72.64%

Ownership

Insider Own1.80%
Insider Trans0.00%
Inst Own5.20%
Inst Trans-2.61%
ROA-34.29%
ROE-70.29%
ROIC-62.86%
Gross Margin19.97%
Oper. Margin-863.92%
Profit Margin-651.27%
SMA20-1.93%
SMA50-8.71%
SMA200-25.48%
Trades-

Technical

Shs Outstand27.45M
Shs Float26.96M
Short Float21.38%
Short Ratio15.59
Short Interest5.76M
52W High1.54 -68.79%
52W Low0.37 29.93%
Volatility14.60% 11.99%
ATR (14)0.05
RSI (14)44.54
Beta1.04
Rel Volume0.48
Avg Volume369.90K
Volume177,720

Performance

Perf Week-12.78%
Perf Month0.97%
Perf Quarter-34.49%
Perf Half Y-26.06%
Perf YTD-38.15%
Perf Year-61.86%
Perf 3Y-97.50%
Perf 5Y-98.94%
Perf 10Y-99.72%
Recom1.00
Target Price4.00
Prev Close0.49
Price0.48
Change %-2.48%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Dec 30, 2024UpgradeDD. Boral CapitalHold → Buy$9+1,772.7%
Nov 30, 2021InitiatedMMaxim GroupBuy$4+732.3%

Peers

Mkt cap
TickerCompanyMkt cap
SNGXSoligenix Inc7.51M
CRMDCorMedix Inc413.10M
KPTIKaryopharm Therapeutics Inc0.39M
FBIOFortress Biotech Inc67.04M
CHRSCoherus Oncology Inc90.02M
ATNMActinium Pharmaceuticals Inc49.99M
PYPDPolypid Ltd134.06M
SPROSpero Therapeutics Inc59.40M
MAIAMAIA Biotechnology Inc63.60M
TNXPTonix Pharmaceuticals Holding Corp75.20M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100
  • Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire)
  • Citius Oncology's Positive Quality of Life Data for LYMPHIR (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe (PR Newswire)
  • Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 (PR Newswire) +11.38%
  • Citius Pharmaceuticals to Participate in October 2026 Investor Conferences (PR Newswire)
  • Citius Pharmaceuticals to Participate in September 2026 Investor Conferences (PR Newswire)
  • Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -25.62%
  • Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
  • Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri (PR Newswire) +6.25%
  • Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment (PR Newswire) +25.45%
  • Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption (PR Newswire) +13.50%
  • Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies (PR Newswire)
  • Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting (PR Newswire)
  • Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -24.76%
  • Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-14-0.340-0.360-0.3801.495.461
2026Q22026-05-15-0.950-0.281-0.9491.6710.232
2026Q12026-02-13-0.3800.430-0.3823.9418.011
2025Q42025-12-25-0.010-0.430-0.4410.000.002
2025Q32025-08-12-0.800-0.505-0.7990.001.922
2025Q22025-05-14-1.270-0.383-1.2720.000.003
2025Q12025-02-14-1.300-1.365-1.3040.000.002
2024Q42024-12-27-1.720-1.527-1.5890.000.003
2024Q32024-08-12-1.500-1.250-1.5670.000.003
2024Q22024-05-14-1.250-1.375-1.3430.000.002
2024Q12024-02-14-1.5003.250-1.4520.0021.301
2023Q42024-01-02-1.750-0.500-1.7460.000.001
2023Q32023-08-14-1.500-1.500-1.3790.000.003
2023Q22023-05-12-1.750-1.000-1.7990.000.003
2023Q12023-02-10-0.500--0.615---
2022Q42022-12-22-1.500-1.250-1.3670.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-18.000-15.125-19.297--
2020FY-11.375-11.500-11.2010.00-
2021FY-5.750-6.000-5.6410.00-
2022FY-5.750-5.375-5.757-103.16
2023FY-5.500-4.000-5.5680.00-
2024FY-5.970-5.720-5.9740.000.00
2025FY-3.380-2.965-2.5503.940.00
2026FY--2.030--10.05
2027FY--1.440--20.52
2028FY--0.670--50.68
2029FY--0.100--74.63
2030FY-0.220--95.47

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-011002.952.952.95
2026Q4S2026-08-181012.952.952.95
2026Q4S2026-08-171009.779.779.77
2026Q4S2026-08-161009.779.779.77
2026Q4S2026-05-261009.779.779.77
2026Q4S2026-05-1820015.859.7721.92
2026Q4S2026-05-1520015.859.7721.92
2026Q4S2026-02-1310021.9221.9221.92
2026Q4S2025-12-3110021.9221.9221.92
2026Q4S2025-12-2420021.5721.2221.92
2026Q4S2025-12-0620021.5721.2221.92
2026Q4S2025-11-1121021.5721.2221.92
2026Q4S2025-11-1021021.5721.2221.92
2026Q4S2025-11-0921021.5721.2221.92

Estimate history

EPS, annual-47.25-29.204-19.297-11.201-5.641-5.757-5.568-5.974-3.383-2.1105
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.567-1.589-1.304-1.272-0.799-0.441-0.382-0.949-0.339
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000007.11
Period201720182019202020212022202320242025TTM
Sales, quarterly0000003.9441.6671.494
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.3340.6481.1572.2235.8395.8486.3547.24718.06827.453
Period201720182019202020212022202320242025MRQ
Shares, quarterly7.2297.2477.7278.76114.47518.06822.37622.37627.453
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue7.110.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A5.690.210.210.190.180.160.150.000.00
Gross Profit1.42-0.21-0.21-0.19-0.18-0.16-0.15-0.00-0.00
Selling, General and Administrative Excl. Other62.8038.3141.7936.5433.1423.3717.5615.6013.43
Research and Development5.939.1611.9114.8217.6612.248.818.606.56
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-61.38-38.53-42.00-36.73-33.32-23.53-17.71-15.60-13.43
Interest Expense0.700.270.000.000.000.010.020.020.02
Unusual Expense0.000.000.000.000.00-0.170.000.00-0.09
Net Income Before Taxes-57.98-38.68-38.85-31.97-33.06-23.05-17.55-15.56-12.54
Income Taxes0.191.060.580.580.580.000.000.000.00
Consolidated Net Income-58.17-39.74-39.43-32.54-33.64-23.05-17.55-15.56-12.54
Net Income From Continuing Operations-46.27-37.43-39.14-32.54-33.64-23.05-17.55-15.56-12.54
Net Income-46.27-37.43-40.19-33.69-33.64-24.51-17.55-15.56-12.54
EPS (Recurring)-1.77-3.38-5.97-5.57-5.76-5.67-11.20-19.30-29.36
EPS (Basic, Before Extraordinaries)-2.11-3.38-5.97-5.57-5.76-5.64-11.20-19.30-29.20
EPS (Diluted)-2.11-3.38-5.97-5.57-5.76-5.64-11.20-19.30-29.20
EBITDA-57.24-38.31-41.79-36.54-33.14-23.37-17.56-15.60-13.43
Non-Operating Income (Expense)4.100.113.154.770.250.320.180.050.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.678.569.355.233.091.450.800.720.78
Price To Sales Ratio2.23--------
Gross Margin19.97--------
Operating Margin-863.92--------
Net Margin-651.27--------
Shares Outstanding27.4518.077.256.355.855.842.221.160.65
Market Capitalization13.5313.5390.70108.72176.92296.3457.8021.9118.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.491.673.940.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.212.051.360.060.040.060.050.05
Gross Profit-0.72-0.382.58-0.06-0.04-0.06-0.05-0.05
Selling, General and Administrative Excl. Other11.0131.8111.608.388.7511.209.9811.00
Research and Development1.051.631.601.641.623.772.132.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.73-32.19-9.02-8.44-8.79-11.26-10.04-11.05
Interest Expense0.410.030.160.100.170.000.000.00
Unusual Expense0.000.000.000.000.00-0.000.00
Net Income Before Taxes-12.03-28.34-9.13-8.48-8.94-11.25-10.02-10.93
Income Taxes-0.11-0.230.260.260.260.260.260.14
Consolidated Net Income-11.92-28.11-9.39-8.74-9.20-11.51-10.28-11.08
Net Income From Continuing Operations-8.86-21.23-8.22-7.96-8.79-10.92-9.77-10.79
Net Income-8.86-21.23-8.22-7.96-8.79-10.92-9.77-11.52
EPS (Recurring)-0.34-0.95-0.38-0.44-0.80-1.27-1.30-1.59
EPS (Basic, Before Extraordinaries)-0.34-0.95-0.38-0.44-0.80-1.27-1.30-1.59
EPS (Diluted)-0.34-0.95-0.38-0.44-0.80-1.27-1.30-1.59
EBITDA-9.97-30.43-8.46-8.38-8.75-11.20-9.98-11.00
Non-Operating Income (Expense)0.123.890.050.050.020.010.020.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.012.993.382.282.152.131.992.09
Price To Sales Ratio2.233.594.23-----
Gross Margin-48.09-22.9065.45-----
Operating Margin-785.39-1,930.96-228.68-----
Net Margin-593.31-1,273.39-208.43-----
Shares Outstanding27.4522.3822.3818.0714.488.767.737.25
Market Capitalization13.1920.1416.1321.1017.7712.8030.9190.70

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.253.2526.4841.7170.0713.867.899.183.20
Short Term Receivables0.000.000.000.000.000.000.000.820.00
Inventories22.298.270.000.000.000.000.000.000.00
Other Current Assets1.402.707.892.852.740.120.050.060.22
Total Current Assets27.9314.2234.3744.5672.8113.987.9410.063.42
Net Property, Plant & Equipment0.820.250.460.650.830.990.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets102.15102.1568.7568.7568.7528.7528.7520.9920.99
Deferred Tax Assets0.22--------
Other Assets0.040.040.040.040.040.060.060.000.00
Total Assets131.16116.65103.61114.00142.4343.7736.7531.0524.42
Short Term Debt Incl. Current Port. of LT Debt1.090.240.220.200.180.330.170.170.17
Accounts Payable13.694.932.931.171.281.862.711.570.60
Other Current Liabilities30.1330.652.633.172.531.911.721.441.69
Total Current Liabilities44.9135.815.784.533.984.104.613.182.47
Long Term Debt0.720.020.260.480.681.020.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities7.996.716.145.564.994.994.99--
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities53.6342.5512.1810.579.6510.109.593.182.47
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity67.5570.0890.83102.83132.1833.6727.1527.8721.95
Total Shareholders Equity67.5570.0890.83102.83132.1833.6727.1527.8721.95
Accumulated Minority Interest9.984.020.600.600.600.000.000.000.00
Total Equity77.5374.1091.43103.43132.7833.6727.1527.8721.95
Total Liabilities & Stockholders Equity131.16116.65103.61114.00142.4343.7736.7531.0524.42
Book Value Per Share3.749.6714.2917.5822.6415.1523.4643.0165.74
Tangible Book Value Per Share-1.91-4.433.485.8310.862.21-1.3810.622.88
Full-Time Employees232322211510977
Price to Book Ratio0.201.291.111.722.241.720.900.841.38
Return on Assets-30.21-35.54-29.91-26.24-24.76-48.24-45.91-45.20-44.79
Return on Equity-54.40-48.65-33.61-28.63-27.80-60.46-56.57-50.33-53.65
Return on Invested Capital-54.83-55.83-35.72-32.56-17.35-50.58-57.31-44.99-47.32
Quick Ratio0.130.175.959.8418.283.411.723.161.39
Current Ratio0.620.405.959.8418.283.411.723.161.39

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-58.17-39.74-39.43-32.54-33.64-23.05-17.55-15.56-12.54
Depreciation4.140.210.210.190.180.160.150.000.00
Other Funds (Non Cash)15.1510.8612.126.724.281.361.330.930.71
Funds from Operations-38.68-27.61-26.52-25.05-28.60-21.53-16.06-14.63-11.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.821.05-1.69-4.010.24-2.72-0.872.200.51
Cash from Operating Activities-34.87-26.55-28.20-29.06-28.36-24.25-16.93-12.44-11.32
Capital Expenditures-12.75-5.75-5.000.000.00-40.01-0.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-12.75-5.75-5.000.000.00-40.01-0.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock49.9032.300.000.030.00120.6422.7311.1517.30
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock49.9032.300.000.030.00120.6422.7311.1517.30
Proceedsfrom Stock Options40.1732.300.000.000.0089.4315.5811.1216.17
Issuance or Reduction of Debt, Net8.631.000.000.000.00-0.170.160.000.00
Change in Long Term Debt8.630.000.000.000.00-0.170.160.000.00
Issuance of Long Term Debt9.630.000.000.000.000.000.160.000.00
Reduction of Long Term Debt-1.000.000.000.000.00-0.170.000.000.00
Net Financing Active Other Cash Flow0.000.009.9713.800.000.000.000.000.00
Other Financing Activities Uses0.000.00-3.830.000.000.000.000.000.00
Cash from Financing Activities58.5433.309.9713.830.00120.4722.9011.1517.30
Net Change in Cash10.921.00-23.23-15.23-28.3656.215.97-1.295.98
Free Cash Flow-34.87-26.55-28.20-29.06-28.36-24.26-16.93-12.44-11.32
Preferred Dividends (Cash Flow)-0.00--0.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-1.060.580.580.580.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments17.014.597.724.256.090.03
Short Term Receivables0.691.084.050.000.000.00
Inventories22.6322.6622.6422.2917.2115.34
Other Current Assets3.013.363.541.401.313.01
Total Current Assets43.3331.6937.9527.9324.6118.37
Net Property, Plant & Equipment0.750.790.840.820.880.92
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets98.1399.85101.57102.15102.15102.15
Deferred Tax Assets---0.22--
Other Assets0.040.210.040.040.040.04
Total Assets142.26132.54140.39131.16127.68121.48
Short Term Debt Incl. Current Port. of LT Debt0.180.171.151.091.110.15
Accounts Payable8.049.4511.0213.6910.099.37
Other Current Liabilities43.4445.3926.0430.1340.6340.36
Total Current Liabilities51.6555.0238.2144.9151.8449.88
Long Term Debt7.000.640.680.720.770.79
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities7.707.808.047.997.517.24
Other Liabilities0.000.000.000.000.000.00
Total Liabilities66.3563.4646.9253.6360.1257.91
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity66.6161.5479.9667.5565.0660.66
Total Shareholders Equity66.6161.5479.9667.5565.0660.66
Accumulated Minority Interest9.307.5413.519.982.502.92
Total Equity75.9169.0893.4777.5367.5663.58
Total Liabilities & Stockholders Equity142.26132.54140.39131.16127.68121.48
Book Value Per Share2.432.753.573.744.496.92
Tangible Book Value Per Share-1.15-1.71-0.97-1.91-2.56-4.74
Full-Time Employees---23--
Price to Book Ratio0.200.250.210.280.230.18
Return on Assets-34.29-36.38-27.49-30.21-35.83-39.63
Return on Equity-70.29-75.61-49.37-54.40-53.42-60.06
Return on Invested Capital-12.04-34.15-10.19-11.66-13.35-17.77
Quick Ratio0.400.160.400.130.140.06
Current Ratio0.840.580.990.620.470.37

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-11.92-28.11-9.39-8.74-9.20-11.51
Depreciation1.761.760.560.060.040.06
Other Funds (Non Cash)3.993.794.462.922.722.70
Funds from Operations-6.27-22.79-4.12-5.50-6.18-8.49
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.4021.49-8.89-6.380.773.95
Cash from Operating Activities-8.68-1.30-13.01-11.88-5.41-4.54
Capital Expenditures-2.00-0.60-4.40-5.750.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.00-0.60-4.40-5.750.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock13.46-0.2320.8815.7910.476.04
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock13.46-0.2320.8815.7910.476.04
Proceedsfrom Stock Options3.73-0.2320.8815.7910.476.04
Issuance or Reduction of Debt, Net9.63-1.000.000.001.000.00
Change in Long Term Debt8.630.000.000.000.000.00
Issuance of Long Term Debt9.630.000.000.000.000.00
Reduction of Long Term Debt-1.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.00-2.57
Other Financing Activities Uses0.000.000.000.00-0.000.00
Cash from Financing Activities23.09-1.2320.8815.7911.473.47
Net Change in Cash12.42-3.133.47-1.846.06-1.07
Free Cash Flow-8.68-1.30-13.01-11.88-5.41-4.54

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.38%5.8M27.0M469.68K
2026-10-1521.14%5.7M27.0M525.84K
2026-09-3020.73%5.6M27.0M531.71K
2026-09-1520.63%5.6M27.0M540.20K
2026-08-3120.89%5.6M27.0M557.25K
2026-08-1419.91%5.4M27.0M544.94K
2026-07-3119.13%5.2M27.0M506.03K
2026-07-1518.48%5.0M27.0M616.67K
2026-06-3017.67%4.8M27.0M654.29K
2026-06-1518.11%4.9M27.0M689.00K
2026-05-2918.36%4.9M27.0M821.36K
2026-05-1519.16%5.2M27.0M736.76K
2026-04-3019.85%5.3M26.5M728.28K
2026-04-1518.30%4.0M21.9M557.62K
2026-03-3117.87%3.9M21.9M557.69K
2026-03-1318.51%4.0M21.9M913.75K
2026-02-2715.29%3.3M21.9M787.74K
2026-02-1314.32%3.1M21.9M850.82K
2026-01-3013.42%2.7M20.3M803.06K
2026-01-1514.42%2.9M20.3M1.16M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.037.9395380.000.236-0.0100.000
call5.000.001.000.009.7280.000.000.214-0.0120.000
call7.500.001.000.0010.6840.000.000.205-0.0130.000
put2.501.652.552.170.0008.000.00-0.764-0.0100.000
put5.004.005.000.000.0000.000.00-0.786-0.0110.000
put7.506.507.500.000.0000.000.00-0.795-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-08-218-KCurrent report2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-10UPLOADUpload SubmissionSEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-04SCHEDULE 13D/ASEC
2026-06-02EFFECTEffectiveness filing by commission orderSEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-29CORRESPSEC
2026-05-22S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-088-KCurrent report2026-05-04SEC
2026-04-298-KCurrent report2026-04-23SEC
2026-04-248-KCurrent report2026-04-23SEC
2026-04-24424B5SEC
2026-04-068-KCurrent report2026-04-06SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-108-KCurrent report2026-03-10SEC
2026-03-048-KCurrent report2026-03-04SEC
2026-02-24ARSAnnual report to security holders. 2025-09-30SEC
2026-02-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-02-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-06SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-138-KCurrent report2026-02-09SEC
2026-02-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-2810-K/A2025-09-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC0.93%
VANGUARD CAPITAL MANAGEMENT LLC0.72%
Miller Financial Services LLC0.56%
CITADEL ADVISORS LLC0.46%
JANE STREET GROUP, LLC0.45%
VANGUARD FIDUCIARY TRUST CO0.28%
BlackRock, Inc.0.25%
NORTHERN TRUST CORP0.23%
XTX Topco Ltd0.22%
Asset Advisory Group, Inc.0.21%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.61%
Fidelity Extended Market Index Fund0.60%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund-0.01%

OakChart. CTXR. Cached 15 minutes.

Some panels did not load: insider.